Enclomiphene success rate: what the actual studies show

Last updated 2026-07-30

What does "success rate" actually mean for enclomiphene?

There's no single FDA-approved enclomiphene product, so there's no official label claim to quote. "Success" in the literature usually means one specific thing: the percentage of men whose total testosterone rose from a hypogonadal baseline into the normal reference range (roughly 300-1000 ng/dL, though labs vary) after a defined dosing period, typically 3 to 6 months. That's a narrower definition than most guys have in their head. It doesn't automatically mean better libido, more energy, or improved mood, though those often track with normalized testosterone. It also doesn't mean sperm count went up, only that it didn't crash the way it does on injectable TRT. The most-cited efficacy numbers come from a 2013 pilot study and a handful of smaller trials, plus the earlier Androxal (enclomiphene citrate) development program that never reached FDA approval. Repros Therapeutics ran Androxal through multiple Phase 3 trials in the early 2010s but withdrew the program rather than pursue approval after regulatory back-and-forth over cardiovascular and mood safety data ^[1]. That history matters: everything prescribed today is compounded, not an approved drug with an FDA-reviewed efficacy claim.

What percentage of men see testosterone normalize on enclomiphene?

The most commonly cited figure is that around 80-90% of men with secondary (hypogonadotropic) hypogonadism reach normal total testosterone on enclomiphene, based on pooled data from early Androxal trials and smaller published cohorts. A 2018 review in Sexual Medicine Reviews summarizing the compound's clinical trial history reported that enclomiphene "increased serum total testosterone into the eugonadal range in the majority of hypogonadal men studied" while maintaining sperm parameters better than exogenous testosterone ^[2]. One of the earlier controlled comparisons, published in the Journal of Sexual Medicine (Kim et al., 2016), found that both enclomiphene and testosterone gel raised total testosterone into normal range for most subjects, but enclomiphene did so while preserving LH, FSH, and sperm concentration; the testosterone gel group saw sperm concentration drop significantly by week 16 ^[3]. A smaller, frequently referenced study (Wiehle et al., 2013, in Fertility and Sterility) tested enclomiphene against testosterone gel and placebo in men with secondary hypogonadism and obesity. Enclomiphene restored total testosterone into the normal range in the large majority of treated subjects while testosterone gel suppressed LH and sperm parameters in comparison ^[4]. Here's the honest caveat: these are small trials, mostly under 200 total subjects across arms, run over a decade ago, sponsored by the company developing the drug. Nobody has run a large, independent, multi-year trial since. The 80-90% figure is a reasonable summary of what exists, not a guarantee etched in stone.

How does enclomiphene's success rate compare to testosterone therapy (TRT)?

TRT (injections, gels, pellets) is very effective at raising testosterone numbers, arguably more reliably than enclomiphene in terms of hitting a specific target level, because you're putting the hormone directly into the body rather than asking the pituitary to respond to a stimulus. But the tradeoff is well documented: exogenous testosterone shuts down the hypothalamic-pituitary-gonadal (HPG) axis, dropping LH and FSH, which in turn suppresses sperm production. Studies show this can drop sperm concentration to near-zero in a meaningful share of men within 3-6 months of starting TRT ^[5]. Enclomiphene works upstream instead. It blocks estrogen receptors at the hypothalamus, which the brain reads as "estrogen is low," so it keeps pumping GnRH, which keeps LH and FSH signaling to the testes. Testosterone goes up because the testes are still being told to make it, not because it's being supplied externally. That's the whole reason it preserves fertility potential and testicular volume in a way TRT does not ^{[3] [4]}. | Metric | Enclomiphene | Exogenous TRT |

Is enclomiphene FDA-approved, and does that affect the success data?

No. Enclomiphene citrate, under the brand name Androxal, went through Phase 3 trials but the sponsor withdrew the FDA submission process; it never reached market approval in the United States ^[1]. What's sold today, including anything shipped through a telehealth or direct-to-consumer platform, is a compounded medication, prepared by a licensed compounding pharmacy under a doctor's prescription, not a drug the FDA has reviewed and approved as safe and effective for a specific indication. That distinction matters for interpreting "success rate" claims. The 80-90% figure comes from academic and industry-sponsored trials of the original Androxal formulation, not from FDA-reviewed labeling, because there is no FDA label. Compounded enclomiphene from different pharmacies can vary somewhat in formulation and quality control, since compounding pharmacies are regulated under different rules than manufacturers of approved drugs (state boards of pharmacy oversight, plus FDA's limited authority over compounders under Section 503A of the Federal Food, Drug, and Cosmetic Act) ^[6]. Practically: ask whatever pharmacy is behind your prescription about their testing and sourcing. Enclomiphene Direct's model is built around this exact gap, connecting patients with providers who prescribe compounded enclomiphene filled through a partner pharmacy, with the sourcing made transparent rather than left as a black box.

How is enclomiphene different from clomiphene (Clomid)?

Clomiphene citrate (brand name Clomid) is actually a mixture of two isomers: enclomiphene (the trans-isomer) and zuclomiphene (the cis-isomer), roughly in a 62:38 ratio ^[4]. Enclomiphene is the isomer responsible for most of the anti-estrogenic, LH/FSH-stimulating effect. Zuclomiphene has a much longer half-life (estimated in weeks, versus roughly 10 hours for enclomiphene) and is thought to contribute more of the estrogen-like side effects some men report on clomiphene, like mood changes and visual disturbances ^[4]. The theoretical appeal of isolated enclomiphene is getting the testosterone-raising effect without the zuclomiphene baggage accumulating in the system over months of use. Whether that theoretical advantage translates into meaningfully fewer side effects in practice hasn't been nailed down by large head-to-head trials; the comparative studies that exist are small. It's a plausible, mechanistically sound argument, not a proven clinical outcome. Clomiphene, unlike enclomiphene, does have FDA-approved indications, though for female infertility, not for male hypogonadism; use in men is off-label ^[7]. Enclomiphene has no FDA-approved indication at all.

Does enclomiphene actually preserve fertility, or just avoid making it worse?

This is the question worth being careful with, because the marketing shorthand ("preserves fertility") oversells what the data supports. What the trials show is that enclomiphene, unlike TRT, does not suppress LH, FSH, or sperm parameters the way exogenous testosterone does ^{[3] [4]}. That's a meaningfully different claim than "enclomiphene improves your fertility" or "enclomiphene guarantees you'll conceive." For a man who is otherwise fertile and needs testosterone support, staying off exogenous TRT and using enclomiphene instead means his sperm production machinery keeps running, because LH and FSH keep signaling to the testes. That's the practical, defensible claim. It's a preservation story, not an enhancement story, for most men. For men who already have low sperm counts or infertility from causes other than TRT-induced suppression, enclomiphene alone is not established as a fertility treatment, and it isn't a substitute for a reproductive endocrinology workup. If fertility is the primary goal, that's a conversation for a doctor who can order a semen analysis and look at the whole picture, not a decision to make off a success-rate statistic. See enclomiphene before and after for how these changes typically show up over time in patients tracking labs.

How long does it take to see results, and how is "success" measured along the way?

Most trial protocols recheck testosterone at 3, 6, 12, and 16 weeks. In the Wiehle 2013 trial, meaningful testosterone increases were seen within the first month, with levels generally stabilizing by around 6-12 weeks of consistent dosing ^[4]. Symptom improvement (energy, libido, mood) tends to lag the lab numbers by a few weeks, which is consistent with how slowly androgen receptors and downstream tissue changes respond even after serum levels normalize. A rough week-by-week expectation, based on published trial timelines: | Week | What's typically tracked | What trials showed |

What dose gets used in the studies behind these success numbers?

Doses studied in the Androxal-era trials generally ranged from 12.5 mg to 25 mg daily, taken orally ^{[3] [4]}. Some later off-label prescribing patterns use lower or alternate-day dosing, or start at 12.5 mg and titrate up based on follow-up labs. There's no single FDA-approved dose because there's no approved product; dosing in practice is set by the prescribing physician, often based on the trial doses that showed the best testosterone response with the fewest side effects. Higher doses aren't automatically better. Some men see adequate normalization at 12.5 mg and don't need to go higher; going straight to 25 mg without checking labs first is a common and avoidable mistake. Since this is compounded medication prescribed off-label, dose titration based on your own bloodwork matters more than chasing whatever dose someone else says worked for them.

Who tends to respond well, and who doesn't?

Trial populations were mostly men with secondary hypogonadism, meaning the problem originates at the hypothalamus/pituitary level rather than testicular failure. Enclomiphene depends on the testes being able to respond to LH signaling; if the testes themselves are the problem (primary hypogonadism, from conditions like Klinefelter syndrome or prior testicular injury), the same upstream stimulation strategy is far less likely to work, because you can send all the LH signal you want and damaged testes may simply not respond. Men with significant obesity were specifically studied in some of the enclomiphene trials, since obesity is strongly associated with lower testosterone and altered estrogen signaling; those subjects still generally normalized on treatment ^[4]. Age, baseline testosterone severity, and pituitary function all plausibly affect individual response, but the published data isn't granular enough to give reliable subgroup success rates beyond the broad secondary-vs-primary distinction. If you're not sure which category you fall into, that's determined by an LH/FSH panel alongside total and free testosterone, not by symptoms alone. A doctor reviewing your labs should be able to tell you within one visit whether enclomiphene is even mechanistically a reasonable option for your case.

What are the known side effects and how often do they happen?

Reported side effects across the enclomiphene trials include headache, mild mood changes, occasional visual disturbances, and modest estradiol fluctuation, generally described as less frequent or severe than with clomiphene, though direct comparative frequency data across large samples doesn't exist ^{[2] [4]}. Serious adverse events were uncommon in the published trials, but sample sizes were small enough that rare risks wouldn't necessarily show up. The Androxal program's regulatory history included scrutiny over cardiovascular and mood-related signals during FDA review discussions, which contributed to the sponsor not pursuing approval to completion ^[1]. That doesn't mean the drug is dangerous; it means the evidence base wasn't large enough, or wasn't presented in a way that satisfied FDA's bar for a new drug approval, and nobody has since run the trials needed to settle it definitively. Anyone starting enclomiphene should get baseline labs (total and free testosterone, LH, FSH, estradiol) and a follow-up panel at 6-12 weeks, both to confirm it's working and to catch anything unexpected early.

Frequently asked questions

What percentage of men respond to enclomiphene?

Published trials and reviews put testosterone normalization at roughly 80-90% of men with secondary hypogonadism, usually within 6-12 weeks of consistent dosing ^[2][4]. That figure comes from small, mostly decade-old studies tied to the never-approved Androxal program, not from a large modern trial, so treat it as a reasonable estimate rather than a guarantee.

Does enclomiphene really preserve fertility better than TRT?

Trials show enclomiphene maintains LH, FSH, and sperm parameters much better than exogenous testosterone, which suppresses all three ^[3][4]. That's a preservation effect, not proof it improves fertility outcomes or pregnancy rates. If fertility is your main goal, a semen analysis and a reproductive specialist matter more than the drug choice alone.

Is enclomiphene FDA-approved?

No. The Androxal enclomiphene program went through Phase 3 trials but was withdrawn before FDA approval ^[1]. Everything available today is compounded medication prescribed off-label by a physician, filled through a compounding pharmacy, not an FDA-approved drug with reviewed labeling.

What's the difference between enclomiphene and clomiphene (Clomid)?

Clomiphene is a mixture of two isomers, roughly 62% enclomiphene and 38% zuclomiphene ^[7]. Enclomiphene is isolated and thought to drive most of the testosterone-raising effect, while zuclomiphene has a much longer half-life and is linked to more of clomiphene's estrogen-like side effects ^[8]. Clomiphene itself is FDA-approved, but only for female infertility, not for men.

How long does enclomiphene take to raise testosterone?

In published trials, testosterone increases were often measurable within 2-4 weeks and generally stabilized by 6-12 weeks of consistent daily dosing ^[4]. Symptom improvement (libido, energy, mood) tends to trail the lab changes by a few additional weeks.

What dose of enclomiphene is used in studies?

Trial doses ranged mostly from 12.5 mg to 25 mg daily, taken orally ^[3][4]. There's no single approved dose since there's no FDA-approved product; a prescribing doctor typically starts low and adjusts based on follow-up labs rather than a fixed protocol.

Can enclomiphene fail to work?

Yes. It depends on the testes being able to respond to LH signaling, so men with primary (testicular) hypogonadism generally respond poorly, unlike men with secondary (pituitary/hypothalamic) hypogonadism ^[4]. Obesity, baseline severity, and individual pituitary function likely affect response too, though the published data doesn't break this down precisely.

Is enclomiphene safer than TRT for fertility-focused men?

For men wanting to avoid HPG axis suppression, enclomiphene has a mechanistic and trial-based advantage: it preserves LH, FSH, and sperm parameters where TRT suppresses them ^[3][4]. It is not risk-free; headache, mood changes, and estradiol fluctuations are reported, and long-term, large-scale safety data is limited ^[2].

Why did enclomiphene never get FDA approved?

The developer, Repros Therapeutics, ran Androxal through Phase 3 trials in the early 2010s but withdrew from the approval process amid FDA questions around cardiovascular and mood safety data, rather than complete the review ^[1]. It was a business and regulatory decision, not a public safety recall.

Where does compounded enclomiphene come from if it's not FDA-approved?

Licensed compounding pharmacies prepare it from raw enclomiphene citrate under a physician's prescription, under rules distinct from FDA's approval pathway for manufactured drugs (see 21 U.S.C. § 353a governing pharmacy compounding) ^[6]. Quality and consistency can vary by pharmacy, so ask about testing and sourcing before starting.

Does enclomiphene shrink the testicles like TRT can?

No, trial data shows enclomiphene preserves testicular stimulation because LH and FSH signaling stays intact, unlike TRT which suppresses that signaling and can lead to testicular atrophy over time ^[3][4]. This is one of the main reasons men choose it over injectable testosterone.

How is enclomiphene success measured differently from TRT success?

TRT success is usually just "did testosterone reach target range," since suppression of natural production is expected and accepted. Enclomiphene success in trials means testosterone normalized while LH, FSH, and sperm parameters were also maintained, a higher bar that reflects its fertility-preservation rationale ^[2][3].

Sources

1. U.S. National Library of Medicine, ClinicalTrials.gov (Repros Therapeutics Androxal Phase 3 program): Androxal (enclomiphene citrate) went through Phase 3 trials for secondary hypogonadism but did not reach FDA approval
2. Sexual Medicine Reviews, enclomiphene citrate clinical review: Enclomiphene increases serum total testosterone into the eugonadal range in the majority of hypogonadal men studied while better preserving sperm parameters than exogenous testosterone
3. Journal of Sexual Medicine, Kim et al. comparative trial: Enclomiphene and testosterone gel both raised total testosterone, but enclomiphene preserved LH, FSH, and sperm concentration where testosterone gel suppressed them
4. Fertility and Sterility, Wiehle et al. 2013 enclomiphene trial: Enclomiphene restored total testosterone to normal range in men with secondary hypogonadism and obesity while maintaining LH, FSH, and sperm parameters better than testosterone gel
5. Journal of Clinical Endocrinology & Metabolism, testosterone therapy and spermatogenesis suppression: Exogenous testosterone therapy suppresses LH, FSH, and sperm production, in some cases to azoospermia
6. U.S. Food and Drug Administration, compounding law overview (21 U.S.C. § 353a): Pharmacy compounding of drugs like enclomiphene is governed by Section 503A of the Federal Food, Drug, and Cosmetic Act, distinct from the approval pathway for manufactured drugs
7. FDA-approved labeling reference for clomiphene citrate (Clomid): Clomiphene citrate is FDA-approved for female ovulatory dysfunction, not for male hypogonadism